Breaking

BofA's Countrywide Is Ordered to Pay $1.3B for Defective Loans
Tweet TWEET

Scientific Journal Article Demonstrates Superiority of n3D’s Bio-Assembler

  Scientific Journal Article Demonstrates Superiority of n3D’s Bio-Assembler  Business Wire  NOKOMIS, Fla. -- September 26, 2013  A recent study published in the scientific journal Biochimica et Biophysica Acta provides an illuminating demonstration of the superiority of three-dimensional cell cultures produced by Rainbow Coral Corp. (OTCBB: RBCC) partner Nano3D Biosciences’ technology over traditional two-dimensional cultures.  Produced by researchers from Houston’s Baylor College of Medicine and the Methodist Hospital Research Institute, the study reports on experiments into the transdifferentiation of vascular smooth muscle cells into calcifying vascular cells. The group used n3D’s Bio-Assembler technology to magnetically levitate their cell cultures in order to produce more lifelike tissues.  The study found that the cells grew more rapidly using in 3-D than 2-D, and differentiated in days rather than weeks. The published piece is yet more evidence to the scientific community that the Bio-Assembler is an essential tool for all kinds of cellular research, including disease models.  “The Bio-Assembler represents a new evolution in cell culture technology,” said RBCC CEO Patrick Brown. “Thanks to high-profile research being conducted using this system, word is being spread very rapidly as to the unparalleled utility and efficiency afforded by the Bio-Assembler.”  RBCC formed a joint venture with n3D to market and develop the Bio-Assembler last year. Rainbow Biosciences is dedicated to the marketing and development of new medical and research technology innovations designed to help capture a growing share of a booming biotech industry alongside Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN).  For more information on RBCC’s partnership with n3D and other biotech initiatives, please visit www.rainbowbiosciences.com/investors.html.  About Rainbow Biosciences  Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB:RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visitwww.RainbowBioSciences.com. For investment information and performance data on the Company, please visitwww.RainbowBioSciences.com/investors.html.  Notice Regarding Forward-Looking Statements  Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.  Contact:  Rainbow Coral Corp. Patrick Brown, 850-269-7230 President and CEO info@rainbowcoral.com